Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2012 - 2020)

Ionis Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $307.7 million for Q3 2020.

• In Q3 2020, Long-Term Deferred Tax rose 7.98% year-over-year to $307.7 million; the TTM figure through Sep 2020 stood at $307.7 million (up 7.98% YoY), while the FY2019 annual figure was $305.6 million, up 5.08% from the prior year.
• Long-Term Deferred Tax was $307.7 million for Q3 2020 at Ionis Pharmaceuticals, up from $306.0 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $309.6 million in Q1 2020 to a low of $276.4 million in Q2 2019.
• Historically, Long-Term Deferred Tax has averaged $294.8 million across 3 years, with a median of $298.2 million in 2018.
• The sharpest annual moves came in 2019 and 2020: Long-Term Deferred Tax grew 5.08% in 2019, then climbed 11.67% in 2020.
• A 3-year view of Long-Term Deferred Tax shows it stood at $290.8 million in 2018, then gained by 5.08% to $305.6 million in 2019, then rose by 0.71% to $307.7 million in 2020.
• The last three Long-Term Deferred Tax figures came in at $307.7 million (Q3 2020), $306.0 million (Q2 2020), and $309.6 million (Q1 2020), per Business Quant data.